Search

Your search keyword '"M. Trauner"' showing total 1,235 results
Start Over Author "M. Trauner"
1,235 results on '"M. Trauner"'

1. URSODEOXYCHOLIC ACID IN PATIENTS WITH CHRONIC HEART FAILURE. A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, CROSSOVER TRIAL

Author

S. von Haehling, J. C. Schefold, E. A. Jankowska, J. Springer, A. Vazir, P. R. Kalra, A. Sandek, G. Fauler, T. Stojakovic, M. Trauner, P. Ponikowski, H-D. Volk, W. Doehner, A. J. S. Coats, P. A. Poole-Wilson, and S. D. Anker

Subjects
Therapeutics. Pharmacology, RM1-950, Diseases of the circulatory (Cardiovascular) system, RC666-701
Abstract

Цель. Оценить влияние урсодеоксихолевой кислоты (УДХК) на функцию эндотелия и маркеры воспаления у больных хронической сердечной недостаточностью (ХСН). Введение. Эндотелиальная дисфункция, которая обычно наблюдается у больных ХСН, вносит вклад в возникающее при этом состоянии ограничение способности выполнять физические нагрузки. Бактериальные липополисахариды могут способствовать высвобождению провоспалительных цитокинов и усугублять эндотелиальную дисфункцию. УДХК — желчная кислота, используемая при лечении заболеваний печени с холестазом, обладает противовоспалительным и цитопротекторными свойствами и может способствовать образованию смешанных мицелл вокруг липополисахарида. Эти свойства могут быть полезными для улучшения периферического кровотока у пациентов с ХСН. Материал и методы. Проведено проспективное одноцентровое двойное слепое рандомизированное плацебо-контролируемое перекрестное исследование УДХК у 17 пациентов мужского пола с клинически стабильной ХСН [II/III функционального класса по New York Heart Association (NYHA) с фракцией выброса левого желудочка

Published
2015
Full Text
View/download PDF

2. Noninvasive assessment of liver disease severity in patients with nonalcoholic fatty liver disease and type 2 diabetes

Author

G. Pennisi, M. Enea, V. Falco, G.P. Aithal, N. Palaniyappan, Y. Yilmaz, J. Boursier, C. Cassinotto, V. de Lédinghen, W.K. Chan, S. Mahadeva, P. Eddowes, P. Newsome, T. Karlas, J. Wiegand, V. Wai-Sun Wong, J.M. Schattenberg, C. Labenz, W. Kim, M.S. Lee, M. Lupsor-Platon, J.F.L. Cobbold, J. Fan, F. Shen, K. Staufer, M. Trauner, R. Stauber, A. Nakajima, M. Yoneda, E. Bugianesi, R. Younes, S. Gaia, M. Zheng, C. Cammà, Q.M. Anstee, F.E. Mózes, M. Pavlides, and S. Petta

Subjects
Hepatology, Gastroenterology
Published
2023

3. Hepatic T1-time predicts cardiovascular risk in all-comers referred for cardiovascular magnetic resonance

Author

K Mascherbauer, C Dona, M Koschutnik, V Dannenberg, C Nitsche, F Duca, D Beitzke, C Loewe, E Waldmann, M Trauner, P Bartko, G Goliasch, J Mascherbauer, C Hengstenberg, and A Kammerlander

Subjects
Cardiology and Cardiovascular Medicine
Abstract

Background Liver damage is frequently observed in patients with cardiovascular disease (CVD) but infrequently quantified. We hypothesized that in patients with CVD undergoing cardiac magnetic resonance (CMR), liver T1-times indicate liver damage and are associated with cardiovascular outcome. Methods We measured hepatic T1-times, displayed on standard cardiac T1-maps, in an all-comer CMR-cohort. At the time of CMR, we assessed validated general liver fibrosis scores. Kaplan-Meier estimates and Cox-regression models were used to investigate the association between hepatic T1-times and a composite endpoint of non-fatal myocardial infarction, heart failure hospitalization, and death. Results 1022 participants (58±18 y/o, 47% female) were included (972 patients, 50 controls). Hepatic T1-times were 590±89ms in patients and 574±45ms in controls (p=0.052). They were significantly correlated with cardiac size and function, presence of atrial fibrillation, NT-pro-BNP levels, and gamma-glutamyl-transferase levels (p Conclusion Hepatic T1-times on standard CMR scans were significantly associated with cardiac size and function, comorbidities, natriuretic peptides, and independently predicted cardiovascular mortality and morbidity. A hepatic T1-time >610ms seems to indicate excessive risk. Funding Acknowledgement Type of funding sources: None.

Published
2022

6. Wirksamkeit und Sicherheit einer zweiten Behandlung mit Immun-Checkpoint-Inhibitoren bei PatientInnen mit hepatozellulärem Karzinom

Author

B Scheiner, K Pomej, T Pressiani, A Cammarota, TW Fründt, J von Felden, K Schulze, D Rössler, V Himmelsbach, F Finkelmeier, A Deibel, AR Siebenhüner, K Shmanko, P Radu, B Schwacha, MP Ebert, A Teufel, A Djanani, F Hucke, L Balcar, M Venerito, F Sinner, M Trauner, A D'Alessio, DJ Pinato, M Peck-Radosavljevic, J Dufour, A Weinmann, AE Kremer, ENDe Toni, L Rimassa, and M Pinter

Published
2022

10. Impact of COVID-19 on liver transplantation in Austria

Author

L Hartl, E Tatscher, M Weiß, L Balcar, G Semmler, R Strassl, M Jachs, DJ Bauer, B Scheiner, M Mandorfer, T Soliman, G Berlakovich, H Tilg, S Schneeberger, M Trauner, P Fickert, T Reiberger, and I Graziadei

Published
2022

27. Systematic review of response criteria and endpoints in autoimmune hepatitis by the International Autoimmune Hepatitis Group

Author

Arıkan, Çiğdem (ORCID 0000-0002-0794-2741 & YÖK ID 240198), Pape, S.; Snijders R.J.; Gevers, T.J.; Chazouilleres, O.; Dalekos, G.N.; Hirschfield, G.M.; Lenzi, M.; Trauner, M.; Manns, M.P.; Vierling, J.M.; Montano Loza, A.J.; Lohse, A.W.; Schramm, C.; Drenth, J.P.; Heneghan, M.A.; International Autoimmune Hepatitis Group (IAIHG), School of Medicine, Arıkan, Çiğdem (ORCID 0000-0002-0794-2741 & YÖK ID 240198), Pape, S.; Snijders R.J.; Gevers, T.J.; Chazouilleres, O.; Dalekos, G.N.; Hirschfield, G.M.; Lenzi, M.; Trauner, M.; Manns, M.P.; Vierling, J.M.; Montano Loza, A.J.; Lohse, A.W.; Schramm, C.; Drenth, J.P.; Heneghan, M.A.; International Autoimmune Hepatitis Group (IAIHG), and School of Medicine

Abstract

Background and aims: Autoimmune hepatitis (AIH) has been well characterised and codified through the development of diagnostic criteria. These criteria have been adapted and simplified and are widely used in clinical practice. However, there is a need to update and precisely define the criteria for both treatment response and treatment. Methods: a systematic review was performed and a modified Delphi consensus process was used to identify and redefine the response criteria in autoimmune hepatitis. Results: the consensus process initiated by the International Autoimmune Hepatitis Group proposes that the term 'complete biochemical response' defined as 'normalization of serum transaminases and IgG below the upper limit of normal' be adopted to include a time point at 6 months after initiation of treatment. An insufficient response by 6 months was a failure to meet the above definition. Non-response was defined as '<50% decrease of serum transaminases within 4 weeks after initiation of treatment'. Remission is defined as liver histology with a Hepatitis Activity Index <4/18. Intolerance to treatment was agreed to stand for 'any adverse event possibly related to treatment leading to potential drug discontinuation'. Conclusions: these definitions provide a simple and reproducible framework to define treatment response and non-response, irrespective of the therapeutic intervention. A consensus on endpoints is urgently required to set a global standard for the reporting of study results and to enable inter-study comparisons. Future prospective database studies are needed to validate these endpoints. Lay summary: consensus among international experts on response criteria and endpoints in autoimmune hepatitis is lacking. A consensus on endpoints is urgently required to set a global standard for the reporting of study results and to enable the comparison of results between clinical trials. Therefore, the International Autoimmune Hepatitis Group (IAIHG) herein presents a statem, YAEL Foundation

Published
2022

28. Systematic review of response criteria and endpoints in autoimmune hepatitis by the International Autoimmune Hepatitis Group

Author

Simon Pape, Romée J.A.L.M. Snijders, Tom J.G. Gevers, Oliver Chazouilleres, George N. Dalekos, Gideon M. Hirschfield, Marco Lenzi, Michael Trauner, Michael P. Manns, John M. Vierling, Aldo J. Montano-Loza, Ansgar W. Lohse, Christoph Schramm, Joost P.H. Drenth, Michael A. Heneghan, P. Almasio, F. Alvarez, R. Andrade, C. Arikan, D. Assis, E. Bardou-Jacquet, M. Biewenga, E. Cancado, N. Cazzagon, O. Chazouillères, G. Colloredo, M. Cuarterolo, G. Dalekos, D. Debray, M. Robles-Díaz, J. Drenth, J. Dyson, C. Efe, B. Engel, S. Ferri, R. Fontana, N. Gatselis, A. Gerussi, E. Halilbasic, N. Halliday, M. Heneghan, G. Hirschfield, B. van Hoek, M. Hørby Jørgensen, G. Indolfini, R. Iorio, S. Jeong, D. Jones, D. Kelly, N. Kerkar, F. Lacaille, C. Lammert, B. Leggett, M. Lenzi, C. Levy, R. Liberal, A. Lleo, A. Lohse, S. Ines Lopez, E. de Martin, V. McLin, G. Mieli-Vergani, P. Milkiewicz, N. Mohan, L. Muratori, G. Nebbia, C. van Nieuwkerk, Y. Oo, A. Ortega, A. Páres, T. Pop, D. Pratt, T. Purnak, G. Ranucci, S. Rushbrook, C. Schramm, A. Stättermayer, M. Swain, A. Tanaka, R. Taubert, D. Terrabuio, B. Terziroli, M. Trauner, P. Valentino, F. van den Brand, A. Villamil, S. Wahlin, H. Ytting, K. Zachou, M. Zeniya, Pape, S, Snijders, R, Gevers, T, Chazouilleres, O, Dalekos, G, Hirschfield, G, Lenzi, M, Trauner, M, Manns, M, Vierling, J, Montano-Loza, A, Lohse, A, Schramm, C, Drenth, J, Heneghan, M, Almasio, P, Alvarez, F, Andrade, R, Arikan, C, Assis, D, Bardou-Jacquet, E, Biewenga, M, Cancado, E, Cazzagon, N, Colloredo, G, Cuarterolo, M, Debray, D, Robles-Diaz, M, Dyson, J, Efe, C, Engel, B, Ferri, S, Fontana, R, Gatselis, N, Gerussi, A, Halilbasic, E, Halliday, N, van Hoek, B, Horby Jorgensen, M, Indolfini, G, Iorio, R, Jeong, S, Jones, D, Kelly, D, Kerkar, N, Lacaille, F, Lammert, C, Leggett, B, Levy, C, Liberal, R, Lleo, A, Ines Lopez, S, de Martin, E, Mclin, V, Mieli-Vergani, G, Milkiewicz, P, Mohan, N, Muratori, L, Nebbia, G, van Nieuwkerk, C, Oo, Y, Ortega, A, Pares, A, Pop, T, Pratt, D, Purnak, T, Ranucci, G, Rushbrook, S, Stattermayer, A, Swain, M, Tanaka, A, Taubert, R, Terrabuio, D, Terziroli, B, Valentino, P, van den Brand, F, Villamil, A, Wahlin, S, Ytting, H, Zachou, K, Zeniya, M, Arıkan, Çiğdem (ORCID 0000-0002-0794-2741 & YÖK ID 240198), Pape, S., Snijders R.J., Gevers, T.J., Chazouilleres, O., Dalekos, G.N., Hirschfield, G.M., Lenzi, M., Trauner, M., Manns, M.P., Vierling, J.M., Montano Loza, A.J., Lohse, A.W., Schramm, C., Drenth, J.P., Heneghan, M.A., International Autoimmune Hepatitis Group (IAIHG), School of Medicine, Gastroenterology and hepatology, AII - Infectious diseases, and Amsterdam Gastroenterology Endocrinology Metabolism

Subjects
autoimmune hepatitis, Hepatology, endpoints, endpoint, insufficient response, Renal disorders Radboud Institute for Molecular Life Sciences [Radboudumc 11], remission, non-response, complete biochemical response, intolerance, Autoimmune hepatitis, Complete biochemical response, Endpoints, Insufficient response, Intolerance, Non-response, Remission, Medicine, autoimmune hepatiti
Abstract

Background and aims: Autoimmune hepatitis (AIH) has been well characterised and codified through the development of diagnostic criteria. These criteria have been adapted and simplified and are widely used in clinical practice. However, there is a need to update and precisely define the criteria for both treatment response and treatment. Methods: a systematic review was performed and a modified Delphi consensus process was used to identify and redefine the response criteria in autoimmune hepatitis. Results: the consensus process initiated by the International Autoimmune Hepatitis Group proposes that the term 'complete biochemical response' defined as 'normalization of serum transaminases and IgG below the upper limit of normal' be adopted to include a time point at 6 months after initiation of treatment. An insufficient response by 6 months was a failure to meet the above definition. Non-response was defined as ', YAEL Foundation

Published
2022

30. Einfluss der Augmentationstherapie mit Alpha1-Antitrypsin auf den Leberphänotyp von Individuen mit klassischem Alpha1-Antitrypsin-Mangel (Genotyp Pi*ZZ)

Author

Matthias C. Reichert, C Lindhauer, M Mandorfer, Robert Bals, Elmar Aigner, Thorhauge K Holtz, Joan Genescà, Rembert Koczulla, Carolin V. Schneider, Aleksander Krag, V Woditsch, A Teumer, Joanna Chorostowska-Wynimko, Pavel Strnad, Christian Trautwein, Karim Hamesch, William J.H. Griffiths, Marc Miravitlles, Malin Fromme, Federica Benini, Sabina Janciauskiene, M Trauner, Frank Lammert, V Pereira, Mònica Pons, and J Voß

Published
2021

32. Von Willebrand Factor (VWF) propeptide levels are similarly accurate for assessing portal hypertension as compared to VWF antigen

Author

M. Trauner, Rodrig Marculescu, I Villesen, Bernhard Scheiner, D Leeming, Philipp Schwabl, Benedikt Simbrunner, Matthias Pinter, AF Stättermayer, Peter Quehenberger, Thomas Reiberger, Mattias Mandorfer, M Karsdal, David Bauer, and Rafael Paternostro

Subjects
medicine.medical_specialty, Endocrinology, Antigen, Von Willebrand factor, biology, business.industry, Internal medicine, biology.protein, medicine, Portal hypertension, Protein precursor, business, medicine.disease
Published
2021

33. The impact of betablocker treatment on cancer prognosis in patients with advanced hepatocellular carcinoma receiving sorafenib treatment

Author

Bernhard Scheiner, M. Trauner, Lorenz Balcar, Tobias Meischl, Matthias Pinter, Christian Müller, Thomas Reiberger, Katharina Pomej, and Mattias Mandorfer

Subjects
Oncology, medicine.medical_specialty, business.industry, Internal medicine, Hepatocellular carcinoma, Sorafenib treatment, Medicine, In patient, business, medicine.disease, Cancer prognosis
Published
2021

34. Clinical significance of substantially elevated von Willebrand factor antigen levels in patients with advanced chronic liver disease

Author

M. Trauner, Mattias Mandorfer, Lorenz Balcar, Peter Quehenberger, AF Stättermayer, Bernhard Scheiner, RJ Nussbaumer, Rafael Paternostro, Matthias Pinter, Georg Semmler, Benedikt Simbrunner, Lukas Hartl, Thomas Reiberger, Douglas C. Bauer, Katharina Pomej, Mathias Jachs, and J Weinzierl

Subjects
medicine.medical_specialty, business.industry, Internal medicine, medicine, In patient, Clinical significance, business, Chronic liver disease, medicine.disease, Gastroenterology, Von Willebrand factor Antigen
Published
2021

35. Acute haemodynamic response to intravenous propranolol predicts decompensation and mortality in patients with cirrhosis

Author

M. Trauner, Benedikt Simbrunner, Douglas C. Bauer, Mattias Mandorfer, Mathias Jachs, AF Stättermayer, Thomas Reiberger, Rafael Paternostro, Lukas Hartl, Bernhard Scheiner, Philipp Schwabl, and Benedikt Silvester Hofer

Subjects
medicine.medical_specialty, Cirrhosis, Haemodynamic response, business.industry, Internal medicine, Cardiology, medicine, In patient, Decompensation, Propranolol, medicine.disease, business, medicine.drug
Published
2021

36. Covered transjugular intrahepatic portosystemic shunt improves hypersplenism-associated cytopenia in cirrhosis

Author

M. Trauner, Thomas Reiberger, Benedikt Simbrunner, Maria Schoder, Florian Wolf, Mattias Mandorfer, Lukas Hartl, F Karnel, C Vierziger, Douglas C. Bauer, T Grünberger, TA Müllner-Bucsics, Katharina Lampichler, and Mathias Jachs

Subjects
medicine.medical_specialty, Cytopenia, Cirrhosis, business.industry, Internal medicine, medicine.medical_treatment, Medicine, business, medicine.disease, Gastroenterology, Transjugular intrahepatic portosystemic shunt
Published
2021

37. Von Willebrand factor for outcome prediction within different clinical stages of advanced chronic liver disease

Author

Georg Semmler, M. Trauner, Lukas Hartl, Bernhard Scheiner, Peter Quehenberger, Matthias Pinter, Thomas Reiberger, Douglas C. Bauer, Mattias Mandorfer, AF Stättermayer, Benedikt Simbrunner, Mathias Jachs, Lorenz Balcar, and Rafael Paternostro

Subjects
medicine.medical_specialty, Von Willebrand factor, biology, business.industry, Internal medicine, medicine, biology.protein, Chronic liver disease, medicine.disease, Outcome prediction, business, Gastroenterology
Published
2021

39. Covered TIPS improves renal function in patients with cirrhosis and ascites

Author

JP Jonas, Mattias Mandorfer, T Grünberger, Maria Schoder, Lukas Hartl, K Schönhofer, Thomas Reiberger, M. Trauner, F Karnel, TA Müllner-Bucsics, Douglas C. Bauer, Florian Wolf, Mathias Jachs, and Josef Karner

Subjects
medicine.medical_specialty, Cirrhosis, business.industry, Internal medicine, Ascites, medicine, Renal function, In patient, medicine.symptom, medicine.disease, business, Gastroenterology
Published
2021

40. Factor VIII/protein C ratio independently predicts liver-related events but does not reflect the hypercoagulable state in patients with advanced-chronic liver disease

Author

M. Trauner, RJ Nussbaumer, Mathias Jachs, Lorenz Balcar, Ton Lisman, Georg Semmler, Bernhard Scheiner, AF Stättermayer, Benedikt Simbrunner, Matthias Pinter, J Weinzierl, Peter Quehenberger, Douglas C. Bauer, Rafael Paternostro, Thomas Reiberger, Mattias Mandorfer, and Lukas Hartl

Subjects
medicine.medical_specialty, business.industry, Internal medicine, medicine, In patient, Chronic liver disease, medicine.disease, business, Gastroenterology, Protein C, medicine.drug
Published
2021

42. Increasing ACE activity in liver disease impacts on fibrinolysis and inflammation - a potential link to COVID-19

Author

Bernhard Scheiner, David Bauer, Mathias Jachs, Thomas Reiberger, M. Trauner, Benedikt Simbrunner, Georg Semmler, Lukas Hartl, and Mattias Mandorfer

Subjects
Liver disease, Coronavirus disease 2019 (COVID-19), business.industry, medicine.medical_treatment, Immunology, Fibrinolysis, Medicine, Inflammation, Ace activity, medicine.symptom, business, medicine.disease
Published
2021

43. Safety and efficacy of direct oral anticoagulants (DOACs) in Budd-Chiari Syndrome (BCS) - an Austrian multicenter study

Author

Bernhard Scheiner, Mattias Mandorfer, M. Trauner, Elmar Aigner, David Bauer, S Hametner-Schreil, Georg Semmler, S Bartl, R Schöfl, A Lindorfer, Katharina Pomej, Thomas Reiberger, H Hofer, Benedikt Simbrunner, S Gensluckner, Lorenz Balcar, and Christian Datz

Subjects
Pediatrics, medicine.medical_specialty, Multicenter study, business.industry, Budd–Chiari syndrome, medicine, medicine.disease, business
Published
2021

44. Safety of direct oral anticoagulants (DOACs) in patients with advanced liver disease

Author

Ton Lisman, M. Trauner, Benedikt Simbrunner, Peter Quehenberger, Bernhard Scheiner, Jeannette Becker, Teresa Binter, Thomas Reiberger, David Bauer, Katharina Pomej, Mattias Mandorfer, Matthias Pinter, Lorenz Balcar, Georg Semmler, and Lukas Hartl

Subjects
Liver disease, medicine.medical_specialty, business.industry, Internal medicine, medicine, In patient, medicine.disease, business, Gastroenterology
Published
2021

45. Prediction of hepatocellular carcinoma after sustained virologic response in patients with compensated advanced chronic liver disease

Author

Joan Genescà, Philipp Schwabl, Thomas Reiberger, AF Stättermayer, Sergio Rodríguez-Tajes, Peter Ferenci, Benedikt Simbrunner, Lopez S Alonso, David Chromy, Mattias Mandorfer, Sabela Lens, M. Trauner, David Bauer, EL Meyer, ML Manzano, Alberto Zanetto, Rafael Bañares, Michael Schwarz, Francesco Paolo Russo, Karin Kozbial, M Gschwantler, S Hametner-Schreil, R Schöfl, Matthias Pinter, Mònica Pons, Georg Semmler, and Bernhard Scheiner

Subjects
medicine.medical_specialty, business.industry, Internal medicine, Hepatocellular carcinoma, Virologic response, medicine, In patient, Chronic liver disease, medicine.disease, business, Gastroenterology
Published
2021

46. Predicting the outcome of patients with hepatocellular carcinoma treated with immunotherapy - the CRAFITY score

Author

M. Trauner, F Finkelmeier, MP Ebert, Christian Müller, Kornelius Schulze, F Hucke, Lorenz Balcar, Thomas Reiberger, Pompilia Radu, Katharina Pomej, Fabian Kütting, SDe Dossa, D Waldschmidt, Alexander Siebenhüner, Bernhard Scheiner, Andreas Teufel, Nuh N. Rahbari, O Waidmann, Sandra Koch, David J. Pinato, S Spahn, Tobias Meischl, Matthias Pinter, Martha M. Kirstein, and Joachim C. Mertens

Subjects
Oncology, medicine.medical_specialty, business.industry, medicine.medical_treatment, Internal medicine, Hepatocellular carcinoma, medicine, Immunotherapy, medicine.disease, business, Outcome (game theory)
Published
2021

47. Risk evaluation for acute kidney injury and acute-on-chronic liver failure via a blood-based biomarker panel in patients with cirrhosis

Author

Lukas Hartl, Georg Semmler, David Bauer, Mathias Jachs, Mattias Mandorfer, Benedikt Simbrunner, Thomas Reiberger, and M. Trauner

Subjects
medicine.medical_specialty, Cirrhosis, business.industry, Blood based biomarkers, Internal medicine, Acute kidney injury, Medicine, Acute on chronic liver failure, In patient, business, medicine.disease, Gastroenterology, Risk evaluation
Published
2021

48. NSBB-associated VWF-decreases in decompensated cirrhosis indicate a reduced risk of further decompensation, ACLF, and death

Author

Lukas Hartl, Mattias Mandorfer, Ernst Eigenbauer, Douglas C. Bauer, M. Trauner, AF Stättermayer, Mathias Jachs, Matthias Pinter, Philipp Schwabl, Benedikt Simbrunner, Rafael Paternostro, Thomas Reiberger, Bernhard Scheiner, and Peter Quehenberger

Subjects
medicine.medical_specialty, Reduced risk, business.industry, Internal medicine, Cardiology, medicine, Decompensation, Decompensated cirrhosis, business
Published
2021

Catalog

Books, media, physical & digital resources
See catalog results